S095018 Recommended Dose Expansion (RDE) clinical trials

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.